Clinical Trials Logo

Apatinib clinical trials

View clinical trials related to Apatinib.

Filter by:

NCT ID: NCT05512481 Recruiting - Melanoma Clinical Trials

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Start date: September 13, 2022
Phase: Phase 2
Study type: Interventional

Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.

NCT ID: NCT04834674 Not yet recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above. Its incidence accounts for about 15%-20% of primary liver malignancies, showing a gradually increasing trend. Surgical resection is currently the main method for the treatment of ICC. However, most (60% -70%) patients are diagnosed at the advanced stage. Gemcitabine plus cisplatin is the standard first-line incurable resection recommended in international and domestic guidelines. There is not a standard second-line treatment that has progressed after standard first-line chemotherapy. The clinical benefits of immune therapies for HCC are emerging. Early clinical data already show the safety of immune checkpoint inhibition. This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC that has progressed after standard first-line chemotherapy. Patients who were aged 18 to 80 years with a histological or cytological diagnosis of ICC,locally advanced or multiple liver metastases, including progression after gemcitabine chemotherapy, will be enrolled in this trial.

NCT ID: NCT04588987 Recruiting - Neoadjuvant Therapy Clinical Trials

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Start date: October 2020
Phase: Phase 2
Study type: Interventional

GBM is the most common intracranial tumor in adults, accounting for about 40% of all primary intracranial tumors.Although surgery, radiotherapy and chemotherapy have been used, the prognosis of glioma patients is still very poor. The study aim to Evaluate the Safety and efficiency of Using the neoadjuvant therapy with Carilizumab and Apatinib in patients with Recurrent High-Grade Glioma.

NCT ID: NCT04188847 Completed - Chemotherapy Clinical Trials

First-line Chemotherapy for Recurrent Cervical Cancer

Start date: December 6, 2019
Phase: Phase 2
Study type: Interventional

The response rate of traditional first-line chemotherapy for recurrent or persistent advanced cervical cancer was low. This single arm, open, phase II trial would recruit 37 eligible patients. A combination of cisplatin, paclitaxel and apatinib would be given for first 23 patients. If at least 13 patients achieved complete or partial remission, the same regimen would be given for rest patients. The primary end is overall response rate (ORR). The second ends include progression-free survival, overall survival, disease control rate, remission duration, and adverse events. A molecular testing, mainly consisting of genomic analysis, will be carried in the oncologic tissues.

NCT ID: NCT04180007 Recruiting - Metastasis Clinical Trials

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

APT-01
Start date: April 10, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen

NCT ID: NCT03986515 Recruiting - Advanced Cancer Clinical Trials

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Start date: June 4, 2019
Phase: Phase 2
Study type: Interventional

There is still no effective treatment for advanced mucosal melanoma at present. The efficacy of single-agent PD-1 inhibitors is less than 20%. It is urgent to explore regimens to improve the efficacy of PD-1 inhibitors in patients with advanced mucosal melanoma. This study is performed to explore the safety and efficacy of apatinib plus SHR-1210 in patients with advanced mucosa melanoma whose diseases progress after chemotherapy.

NCT ID: NCT03913182 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Start date: April 2, 2019
Phase: Phase 2
Study type: Interventional

It was difficult to obtain clinical benefits through traditional chemotherapy and radiotherapy for the patients who have recurrence or metastasis tumor even though they have received first-line chemotherapy or combined radiotherapy before, but failed.The aim of this study was to evaluate the safety and efficacy of apatinib, an anti-angiogenesis drug, in the treatment of patients with advanced esophageal squamous cell carcinoma who had recurrence or metastasis after radical resection

NCT ID: NCT03889626 Not yet recruiting - Neoplasms Clinical Trials

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Start date: March 22, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer.

NCT ID: NCT03742193 Active, not recruiting - Osteosarcoma Clinical Trials

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

PROACH
Start date: August 11, 2019
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.

NCT ID: NCT03428022 Recruiting - NSCLC Clinical Trials

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC

AFLC
Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

Patients with advanced non-small cell lung cancer (NSCLC) who progress slowly after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors(EGFR-TKI)resistance will be treated with Apatinib and EGFR-TKI. The primary objective is the disease progression free survival of the patients.